Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

198 results about "Galectin" patented technology

Galectins are a class of proteins that bind specifically to β-galactoside sugars, such as N-acetyllactosamine (Galβ1-3GlcNAc or Galβ1-4GlcNAc), which can be bound to proteins by either N-linked or O-linked glycosylation. They are also termed S-type lectins due to their dependency on disulphide bonds for stability and carbohydrate binding. There have been 15 galectins discovered in mammals, encoded by the LGALS genes, which are numbered in a consecutive manner. Only galectin-1, -2, -3, -4, -7, -8, -9, -10 and -12 have been identified in humans. Galectin-5 and -6 are found in rodents, whereas galectin-11, -14 and -15 are uniquely found in sheep and goats. Members of the galectin family have also been discovered in other mammals, birds, amphibians, fish, nematodes, sponges, and some fungi. Unlike the majority of lectins they are not membrane bound, but soluble proteins with both intra- and extracellular functions. They have distinct but overlapping distributions but found primarily in the cytosol, nucleus, extracellular matrix or in circulation. Although many galectins must be secreted, they do not have a typical signal peptide required for classical secretion. The mechanism and reason for this non-classical secretion pathway is unknown.

Neuronal growth factor galectin-1

This invention relates to a remedy for neuropathy, such as nerve injury, nerve degeneration, and hypofunction upon nerve grafting, which contains as the active ingredient galectin-1 having an amino acid sequence represented by SEQ ID NO:1 or its derivative; a protein having the amino acid sequence represented by SEQ ID NO:1 or one having a homology of 90% or more at the amino acid level with the sequence of SEQ ID NO:1 and carrying a disulfide bond(s) at least between Cys at the 16-position (Cys 16) and Cys at the 88-position (Cys 88) among cystein residues at the 2-position (Cys 2), 16-position (Cys 16), 42-position (Cys 42), 60-position (Cys 60), 88-position (Cys 88) and 130-position (Cys 130); and a process for producing the galectin-1 or its derivative protein by using an affinity column having an antibody to the above protein.
Owner:KIRIN BREWERY CO LTD

Compositions, Kits, and Methods for the Diagnosis, Prognosis, Monitoring, Treatment and Modulation of Post-Transplant Lymphoproliferative Disorders and Hypoxia Associated Angiogenesis Disorders Using Galectin-1

The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
Owner:DANA FARBER CANCER INST INC +3

Methods for modulating a population of myeloid-derived suppressor cells and uses thereof

The invention provides for methods of modulating a population of myeloid-derived suppressor cells (MDSCs) in a subject, for treating an autoimmune disease, and also treating cancer in a subject in need thereof. The methods comprise administering to the subject a therapeutically effective amount of an agent that modulates the Tim-3 pathway. The Tim-3 pathway can be activated by a Tim-3 ligand, galectin-9, whereby MDSCs are expanded, or inhibited by an antibody to Tim-3, wherein the expansion of MDSCs is inhibited.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC

Method and assay for early diagnosis of prostate cancer

A method and assay are described for determining prostate cancer and the general stage of progression of such cancer by quantifying levels of expression of different galectin isoforms and / or different levels of promoter methylation of such galectin isoforms.
Owner:UNIV OF MARYLAND

Novel Galactoside Inhibitor of Galectins

The present invention relates to a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method of monitoring development or progression of pulmonary fibrosis in a human subject, a method of monitoring or predicting exacerbation of symptoms in a human subject with pulmonary fibrosis as well as a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms.
Owner:GALECTO BIOTECH

Novel galactoside inhibitors of galectins

Compounds having an effect as i.a. galectin inhibitors, to the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal, where in the galectin is preferably a galectin-3. The novel compounds are defined by the general formula:
Owner:GALECTO BIOTECH

Galactoside inhibitors of galectins

InactiveUS8703720B2Less polarBiocideNervous disorderDiseaseMedicine
Compounds having an effect as i.a. galectin inhibitors, to the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal, where in the galectin is preferably a galectin-3. The novel compounds are defined by the general formula:
Owner:GALECTO BIOTECH

Use of Galectin-3 to promote the re-epithelialization of wounds

Methods for the therapeutic treatment of epithelial wounds in mammals comprising administering to a mammal afflicted with an epithelial wound a therapeutically effective amount of a galectin-3 protein and / or a galectin-7 protein are provided. Pharmaceutical compositions comprising a pharmaceutically suitable carrier or diluent and as an active agent a galectin-3 protein and / or a galectin-7 protein are also provided.
Owner:TRUSTEES OF TUFTS COLLEGE TUFTS UNIV

Method for preparing electrochemical sensor used for detecting concentration of galectin-3 in serum

The invention relates to a preparation method and application of an electrochemical sensor for detecting a blood concentration level of an insulin sensitivity reduction early diagnosis biomarker, namely galectin-3 (Gal-3), causing type II diabetes, and belongs to the technical field of electrochemical detection. The preparation method is characterized by comprising the following steps: respectively synthesizing an N-GNRs-Fe-MOFs@AuPNs sensor substrate modified nano composite material and an AuPt-MB nano composite signal material, enabling a detection antibody capable of being in specific binding to the Gal-3 to be mixed with the AuPt-MB composite material so as to prepare a biological signal probe; conjugating a Gal-3 specific capture antibody on a substrate platform modified by the N-GNRs-Fe-MOFs@AuPNs composite material so as to conveniently and specifically capture a target Gal-3; finally, performing specific binding on the Gal-3 as well as the detection antibody and the capture antibody, thereby obtaining the electrochemical sensor for detecting the blood concentration level of the Gal-3. The sensor is successfully used for detecting the Gal-3 in serum. The electrochemical sensor disclosed by the invention has the advantages of being high in sensitivity, high in specificity, rapid in detection and convenient. An early diagnostic basis is provided for insulin resistance causing the type II diabetes.
Owner:CHONGQING MEDICAL UNIVERSITY

Galectin recognized photosensitizers for photodynamic therapy

Purpurin-carbohydrate conjugates and their method of preparation and use for treatment of cancer cells. The conjugates have the general formula: wherein R6 and R7 taken together are ═NR11 or are independently —OR11, where at least one R11 is preferably a mono or polysaccharide moiety and R1-R8 are various groups formed from carbon and hydrogen and optionally oxygen and nitrogen where R3 and R4 may together from a covalent bond.
Owner:MATTA KHUSHI L DR

Targeted pH-GSH dual-response multifunctional nano-vesicle drug loading system

The invention relates to a targeted pH-GSH dual-response multifunctional nano-vesicle drug loading system. By using cystamine functionalized column [5] aromatic hydrocarbon with pH-GSH dual responsiveness as a host molecule and using a pyridinium modified galactose derivative as a guest molecule, glycosyl-functionalized column [5] aromatic hydrocarbon amphiphilic molecule is prepared through the host-guest interaction; nano-vesicle is formed in a solution through hydrophilic and hydrophobic effect; and an anti-cancer drug is encapsulated in the vesicle cavity so as to construct the targeted pH-GSH dual-response multifunctional nano-vesicle drug loading system. As the surface of vesicle contains galactosyl, biocompatibility of the system can be remarkably raised. Meanwhile, galactosyl can interact with specific galactose binding protein overexpressed on the surface of hepatoma carcinoma cell to realize targeted selective access to cancer cell so as to rapidly release an anti-cancer drugin the cancer cell and raise lethality of cancer cell.
Owner:NORTHWEST A & F UNIV

Galectin-3 binding protein, preparation and application thereof

InactiveCN102942624AAntibacterial agentsPeptide/protein ingredientsGalectin 3 binding proteinThiogalactosides
The invention relates to the field of molecular biology, and in particular to a galectin-3 binding protein, and preparation and application thereof. The galectin-3 binding protein is shown as an amino acid sequence SEQ ID No.1 in the sequence table. The preparation method is as below: using Cynoglossus semilaevis cDNA as a template; conducting PCR amplification by primers F1 and R1; connecting PCR products to an expression vector to obtain a plasmid pETG3BP; conversing BL21DE3 to obtain a transformant BL21 / pETG3BP; inducting by isopropyl-beta-D-thiogalactoside; and purifying the recombinant protein with affinity chromatography column to obtain the galectin-3 binding protein. The galectin-3 binding protein has significant binding ability to various bacteria.
Owner:INST OF OCEANOLOGY - CHINESE ACAD OF SCI

Galectoside inhibitors of galectins

The present invention relates to novel compounds prepared from readily accessible 3-O-propargyl-D-galactopyranoside derivatives and having an effect as i.a., galectin inhibitors, the use of said compounds as a medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to ligands in a mammal, wherein said galectin is preferably a galectin-3. The novel compounds are defined by the general formula (I).
Owner:GALECTO BIOTECH

Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor

Methods and kits using a pharmaceutical composition for use in inhibiting ocular angiogenesis or fibrosis are provided herein, such that composition includes a pharmaceutically suitable carrier or diluent and an amount of the inhibitor composition effective to inhibit the angiogenesis or the fibrosis by inhibiting expression and / or activity of a galectin protein or a portion thereof.
Owner:TUFTS UNIV +1

Novel galectoside inhibitors of galectins

The present invention relates to novel compounds prepared from readily accessible 3-O-propargyl-D-galactopyranoside derivatives and having an effect as i.a., galectin inhibitors, the use of said compounds as a medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to ligands in a mammal, wherein said galectin is preferably a galectin-3. The novel compounds are defined by the general formula (I).
Owner:GALECTO BIOTECH

Identification of two novel biomarkers for niemann-pick disease type c

This invention provides novel biomarkers for Niemann-Pick disease, type C (NPC). In an exemplary embodiment, the invention provides methods for identifying a subject as having NPC. In embodiments, the methods involve detecting the level of biomarker selected from the group comprising i) galectin-3 (LGALS3); ii) cathepsin D (CTSD); iii) LGALS3 and CTSD; and iv) LGALS3 and / or CTSD in combination at least one additional NPC associated biomarker in a sample obtained from the subject. In embodiments, the methods involve comparing the level of biomarker to a reference.
Owner:US DEPT OF HEALTH & HUMAN SERVICES

Anti-galectin-9 antibodies and uses thereof

Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and / or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.
Owner:PURETECH HEALTH LLC +1

Galectin-3C combination therapy for human cancer

The present invention provides a novel composition of matter useful for the treatment of neoplastic diseases. The novel composition is synergistic and comprised of galectin-3C in combination with a proteosome inhibitor, the combination having a pharmacologic activity greater than the expected additive effect of its individual components. Other embodiments of the invention provide novel synergistic compositions of galectin-3C with a proteasome inhibitor capable of reducing or overcoming resistance that develops to the proteasome inhibitor or reducing the adverse side effects from the proteasome inhibitor through increasing the therapeutic efficacy of lower doses.
Owner:TEXAS TECH UNIV SYST +1

Applications of Galectin-10 and specific antibody thereof in preparation of kit for detecting nasopharyngeal carcinoma

The invention relates to a diagnostic marker, particularly discloses a nasopharyngeal carcinoma related marker Galectin-10 (genebank accession number: ID1178), and provides applications of the marker and a specific antibody thereof in preparation of a kit for detecting nasopharyngeal carcinoma, wherein the kit can be an immunohistochemical kit or an enzyme-linked immunosorbent assay kit. The invention provides a new scientific basis for effectively judging human nasopharyngeal disease progression, and can achieve early discovery and early treatment of the nasopharyngeal carcinoma.
Owner:XIANGYA HOSPITAL CENT SOUTH UNIV

Galectin-3 detection nanometer magnetic bead sorting-time resolved immunofluorescence kit

The invention relates to a Galectin-3 detection nanometer magnetic bead sorting-time resolved immunofluorescence kit, which comprises superparamagnetic composite micro-particles with a particle size of 30 nm, a coupling liquid, a blocking solution, a washing liquid, a loading buffer, a fluorescence enhancement solution, a detection buffer, a capture antibody, a detection antibody, Eu<3+> labeled streptavidin and a standard substance. The use of the kit comprises: adopting nanometer magnetic bead sorting and time resolved immunofluorescence adopting a double antibody sandwich method as the base to detect the concentration of Galectin-3 protein in a sample, adopting nanometer magnetic beads coupled with the Galectin-3 capture antibody to enrich the Galectin-3 in the sample, adding the detection antibody, incubating, washing, adding the Eu<3+> labeled streptavidin, incubating, washing again, adding the fluorescence enhancement solution, vibrating for 5 min, adopting light with a wavelength of 337 nm to excite, delaying for 200 microseconds, detecting the emitted fluorescence value at a wavelength of 615 nm, and obtaining the concentration of the Galectin-3 in the sample to be detected through the fluorescence value and the corresponding standard curve, wherein the sample to be detected can further be used for detecting the next target protein.
Owner:AFFILIATED HOSPITAL OF NANTONG UNIV

Galectin-3 to Treat Ovarian Cancer

InactiveUS20150157691A1Reduce eliminateReduce or eliminate the ovarian cancerCompound screeningOrganic active ingredientsGynecologyMotility
The present invention includes a method for the treatment of an advanced ovarian cancer, comprising: identifying a patient with advanced ovarian cancer; and administering to the patient an effective amount of truncated, dominant negative form of Galectin-3 sufficient to reduce the advanced ovarian cancer. In certain aspects, the truncated, dominant negative form of Galectin-3 is provided in an amount sufficient to reduce at least one of growth, motility, invasion, angiogenesis, or prevents Akt / NF-κB activation of the ovarian cancer.
Owner:TEXAS TECH UNIV SYST

Drugs containing galectin 9

Galectin 9 exerts various functions depending on its localizations. On the other hand, galectin 9 is expected as participating in various biological functions. Thus, it has been required to clarify the detailed biological activities of galectin 9 and develop galectin 9-related techniques including development of drugs. Human galectin 9 shows a cytotoxic activity and an apoptosis-inducing activity on tumor cells but shows neither cytotoxic activity nor apoptosis-inducing activity on normal cells. Therefore, it is possible to employ galectin 9 proteins, galectin 9 agonists, galectin 9 antagonists, anti-galectin 9 binding protein antibodies, anti-galectin 9 binding sugar chain antibodies, galectin 9-producing, releasing or inducing substances, etc. as antitumor, antiallergic, immunosuppressive agents, drugs for autoimmune diseases, anti-inflammatory agents and active ingredients for adrenocortical steroid hormone alternatives.
Owner:GALPHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products